UPDATED OVERALL SURVIVAL AND LONG-TERM TRANSFUSION INDEPENDENCE FROM THE PHASE 3 COMMANDS TRIAL IN ERYTHROPOIESIS-STIMULATING AGENT-NAIVE PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (SIE 2026) - Oct 6, 2026 - Abstract #C028; Pres time: Sep 21, 2026; 03:40 PM - 05:10 PM; Location: HALL 2; "In the ph 3 COMMANDS trial (NC- T03682536), luspatercept (LUSPA) significantly improved RBC-TI ≥12 wks with concurrent mean hemoglobin (Hb) in- crease ≥1.5 g/dL (Wks 1–24; primary endpoint) vs epoetin alfa (EA) in pts with ESA-naive transfusion-dependent (TD) LR-MDS. This abstract was accepted and previously presented at the 2026 ASCO Annual Meeting. All rights re- served."
Clinical • P3 data • Acute Myelogenous Leukemia • Hematological Malignancies • Myelodysplastic Syndrome
|
|
V. Santini1; M. G. Della Porta2; A. M. Zeidan3; R. S. Komrokji4; V. Pozharskaya5; Y. Lai5; D. Lopes De Menezes5; M. Ugidos Guerrero5; T. Farazi5; D. Miteva6; B. Aggarwal5; S. Kalsekar7; D. Valcárcel8; P. Fenaux9; J. Shortt10; U. Platzbecker11; G. Garcia-Manero12
|